Novo Nordisk shares dive after heart medicine fails trial
Shares of Novo Nordisk fell on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.
CNBC’s Annika Kim Constantino explains.